Erdal Cavusoglu1, Jonathan D Marmur2, Sudhanva Hegde2, Sunitha Yanamadala2, Olcay A Batuman3, Vineet Chopra4, Gonca Ay5, Calvin Eng4. 1. Division of Cardiology, Department of Medicine, Bronx Veterans Affairs Medical Center, Bronx, NY, USA; Division of Cardiology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. Electronic address: ECavusoglu@aol.com. 2. Division of Cardiology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 3. Division of Hematology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 4. Division of Cardiology, Department of Medicine, Bronx Veterans Affairs Medical Center, Bronx, NY, USA. 5. Department of Biological Sciences, University of Mersin, Mersin, Turkey.
Abstract
OBJECTIVES: To investigate the long-term prognostic significance of baseline plasma MMP-1 levels in a group of well-characterized male patients with known or suspected coronary artery disease, including those presenting with acute coronary syndrome. BACKGROUND: MMP-1 is an interstitial collagenase that is considered the primary enzyme responsible for collagen degradation. In addition, MMP-1 can lead to platelet activation through the PAR1 pathway that is independent of thrombin. METHODS: Baseline plasma MMP-1 levels were measured in 364 male patients who were referred for coronary angiography and followed prospectively for five years for the development of all-cause mortality. RESULTS: After adjustment for a variety of baseline clinical, angiographic and laboratory parameters, baseline plasma MMP-1 levels (analyzed as a continuous variable) were an independent predictor of all-cause mortality at 5 years (HR, 1.49; 95% CI, 1.23-1.80; P < 0.0001). Furthermore, in 3 additional multivariate models that included a wide variety of contemporary biomarkers with established prognostic efficacy (i.e., ST2, GDF-15, Cystatin C, hs-CRP, Myeloperoxidase, NT-proBNP, TIMP-1, Adiponectin, RDW, hemoglobin, and Erythropoietin), MMP-1 remained an independent predictor of all-cause mortality at 5 years. Similar results were obtained when the analyses were restricted to the subpopulation of patients presenting with acute coronary syndrome. CONCLUSIONS: Elevated levels of MMP-1 are associated with an increased risk of long-term all-cause mortality in patients with known or suspected coronary disease that is independent of a variety of clinical, angiographic, and laboratory variables, including a whole host of contemporary biomarkers with established prognostic efficacy representing multiple different pathophysiologic processes.
OBJECTIVES: To investigate the long-term prognostic significance of baseline plasma MMP-1 levels in a group of well-characterized male patients with known or suspected coronary artery disease, including those presenting with acute coronary syndrome. BACKGROUND:MMP-1 is an interstitial collagenase that is considered the primary enzyme responsible for collagen degradation. In addition, MMP-1 can lead to platelet activation through the PAR1 pathway that is independent of thrombin. METHODS: Baseline plasma MMP-1 levels were measured in 364 male patients who were referred for coronary angiography and followed prospectively for five years for the development of all-cause mortality. RESULTS: After adjustment for a variety of baseline clinical, angiographic and laboratory parameters, baseline plasma MMP-1 levels (analyzed as a continuous variable) were an independent predictor of all-cause mortality at 5 years (HR, 1.49; 95% CI, 1.23-1.80; P < 0.0001). Furthermore, in 3 additional multivariate models that included a wide variety of contemporary biomarkers with established prognostic efficacy (i.e., ST2, GDF-15, Cystatin C, hs-CRP, Myeloperoxidase, NT-proBNP, TIMP-1, Adiponectin, RDW, hemoglobin, and Erythropoietin), MMP-1 remained an independent predictor of all-cause mortality at 5 years. Similar results were obtained when the analyses were restricted to the subpopulation of patients presenting with acute coronary syndrome. CONCLUSIONS: Elevated levels of MMP-1 are associated with an increased risk of long-term all-cause mortality in patients with known or suspected coronary disease that is independent of a variety of clinical, angiographic, and laboratory variables, including a whole host of contemporary biomarkers with established prognostic efficacy representing multiple different pathophysiologic processes.
Authors: Kai C Wollert; Tibor Kempf; Timo Peter; Sylvia Olofsson; Stefan James; Nina Johnston; Bertil Lindahl; Rüdiger Horn-Wichmann; Georg Brabant; Maarten L Simoons; Paul W Armstrong; Robert M Califf; Helmut Drexler; Lars Wallentin Journal: Circulation Date: 2007-02-05 Impact factor: 29.690
Authors: Anne M S Belonje; Adriaan A Voors; Peter van der Meer; Wiek H van Gilst; Tiny Jaarsma; Dirk J van Veldhuisen Journal: Circulation Date: 2010-01-04 Impact factor: 29.690
Authors: Michael Lehrke; Martin Greif; Uli C Broedl; Corinna Lebherz; Rüdiger P Laubender; Alexander Becker; Franz von Ziegler; Janine Tittus; Maximilian Reiser; Christoph Becker; Burkhard Göke; Gerhard Steinbeck; Alexander W Leber; Klaus G Parhofer Journal: Cardiovasc Diabetol Date: 2009-09-14 Impact factor: 9.951
Authors: Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos Journal: Arterioscler Thromb Vasc Biol Date: 2018-04-05 Impact factor: 8.311
Authors: Elizabeth K Fletcher; Yanling Wang; Laura K Flynn; Susan E Turner; Jeffrey J Rade; Carey D Kimmelstiel; Paul A Gurbel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos Journal: Arterioscler Thromb Vasc Biol Date: 2021-03-25 Impact factor: 8.311
Authors: Adnan Sultan; Yuting Zheng; Patrick J Trainor; Yong Siow; Alok R Amraotkar; Bradford G Hill; Andrew P DeFilippis Journal: Front Cardiovasc Med Date: 2017-07-31